Author

Silvio Danese 1

1 Humanitas Research Hospital,Milan,Italy

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Laurent Peyrin-Biroulet, Alessandro Armuzzi, Raja Atreya, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charlie Lees, Edouard Louis, Milan Lukas, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

ANDECALIXIMAB (ANTI-MMP9) INDUCTION THERAPY FOR ULCERATIVE COLITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY

William Sandborn, Bal R. Bhandari, Charles Randall, Ziad Younes, Tomasz Romańczyk, Hao Chai, Matthew McKevitt, Sally Zhao, Bittoo Kanwar, John Sundy, Satish Keshav, Silvio Danese

Anti-adhesion therapies

Silvio Danese

Assessment of Budesonide MMX® effectiveness for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the prospective multi-center observational study CORE Practice

Grażyna Rydzewska, Kristine Paridaens, Silvio Danese, Maciej Jesionowski

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1Α STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Silvio Danese

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1Α STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Kartik Raghupathi, Robin Osterhout, Brian Feagan, William J. Sandborn, Courtney Van Biene, Allan Olson, Richard Aranda, Barrett G. Levesque, Silvio Danese

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire, Alessandra Oortwijn, Simon Hatch, Silvio Danese, Toshifumi Hibi, Brian Feagan, William J. Sandborn

BIOMARKER ANALYSES FROM A PHASE 2 STUDY EVALUATING THE ANTI-INTERLEUKIN-13 ANTIBODY TRALOKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Clare Balendran, Jan Kilhamn, Stefan Pierrou, Erika Rehnström, Neil Henderson, Kevin Randall, Glen Hughes, Mikael Knutsson, Fredrik Erlandsson, Mark Hansen, Silvio Danese

Item 1 - 10 / 156
1
2 3 4 5 6 7
...
15 16